Healthcare

The acquisition is a symbol of a much bigger trend.
There has been huge progress in treating this lethal disease.

A Trio of Healthcare Plays Real Money Pro($)

Here's how I'd trade this biotech fund, Incyte and Immunogen.
Amgen's gain is pure insanity from a stock picker's point of view.
Amid the basket's impressive performance, I'm adding Minerva.
The post-earnings trend says the stock will drop after the report.
What to do when central bankers tell you to cut risk.
A lower price means more value for this high-quality stock.

Take a Yellen Opportunity Real Money Pro($)

There's a great entry point in Celgene at $84.
It is preserving its Copaxone franchise, and the executive changes are good news.

Columnist Conversations

If this market has taught us one thing over the past 5 years, it has been to not be dogmatic in our views. Th...
Is this the biotech revolution or the biotech bust? View Small Cap Biotechs Like Never Before: Transparency is...
Market recovers a bit from early losses after European Bourses close at 11:30am EST. Upwardly revised Q2 GDP ...
When I do an article on a stock I do my best to define the risk on the trade. Sometimes I get to follow up an...

REAL MONEY'S BEST IDEAS

Columnist Tweets

BROKERAGE PARTNERS

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.


TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.